Tone T, Kashani-Sabet M, Funato T, Shitara T, Yoshida E, Kashfian B I, Horng M, Fodstadt O, Scanlon K J
Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010.
In Vivo. 1993 Nov-Dec;7(6A):471-6.
Ribozymes, site-specific ribonucleases, are a new vehicle for the manipulation of gene expression. A hammerhead ribozyme designed to cleave the GUC sequence in codon 12 of activated H-ras RNA was cloned into a plasmid (pH beta Apr-1) and transfected into EJ human bladder carcinoma cells. Expression of the ribozyme dramatically reduced H-ras gene expression and inhibited growth of EJ transformants in vitro. In vivo, the H-ras ribozyme suppressed EJ cell tumorigenicity in nude mice. In contrast, the insertion of a mutant ribozyme with no demonstrable cleavage capacity into EJ cells resulted in smaller reductions in H-ras gene expression and growth inhibition while also suppressing tumorigenicity in nude mice. The ribozyme's effect on tumorigenicity was stable, as the cells were cultured for up to five months in vitro prior to injection into nude mice. These studies define a role for anti-oncogenic ribozymes as a unique class of tumor suppressing agents.
核酶,即位点特异性核糖核酸酶,是一种用于操纵基因表达的新型工具。一种旨在切割活化的H-ras RNA第12密码子中GUC序列的锤头状核酶被克隆到一个质粒(pH beta Apr-1)中,并转染到EJ人膀胱癌细胞中。核酶的表达显著降低了H-ras基因的表达,并在体外抑制了EJ转化细胞的生长。在体内,H-ras核酶抑制了裸鼠体内EJ细胞的致瘤性。相比之下,将没有可证明切割能力的突变核酶插入EJ细胞,导致H-ras基因表达和生长抑制的降低幅度较小,同时也抑制了裸鼠的致瘤性。核酶对致瘤性的影响是稳定的,因为在将细胞注射到裸鼠体内之前,它们在体外培养了长达五个月。这些研究确定了抗肿瘤核酶作为一类独特的肿瘤抑制因子的作用。